Compare General Mills, Inc. (GIS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? General Mills, Inc. trades at $37.82 (market cap $19.89B), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.7× General Mills, Inc.'s market cap, and General Mills, Inc. pays a 6.55% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| GIS | VRTX | |
|---|---|---|
Market Cap | $19.89B | $132.79B |
Sector | Consumer Staples | Health |
52-Week High | $51.11 | $529.65 |
52-Week Low | $32.17 | $376.62 |
Enterprise Value | $33.37B | $126.92B |
Dividend Yield | 6.55% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
